<DOC>
	<DOCNO>NCT00426595</DOCNO>
	<brief_summary>Gastroesophageal reflux disease reflux-esophagitis major chronic problem child cerebral palsy mental retardation . Oral administration enteric-coated formulation acid-labile proton pump inhibitor omeprazole often problematic patient may suffer swallow disorder . A suspension omeprazole sodium bicarbonate solution often use administration via gastrostomy tube . This trial aim compare pharmacokinetics omeprazole administer gastrostomy tube suspension pediatric patient cerebral palsy mental retardation versus pharmacokinetics omeprazole administer multi-unit-pellet system ( MUPSÂ® ) . The crossover study consist 2 consecutive treatment period 14 day .</brief_summary>
	<brief_title>Pharmacokinetics Enteral Omeprazole Suspension Patients With Cerebral Palsy Mental Retardation</brief_title>
	<detailed_description />
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Intellectual Disability</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<criteria>Children &gt; 15 kg Cerebral palsy mental retardation swallow disorder Presence gastrostomy tube GERD and/or refluxesophagitis treat omeprazole dose since least 2 week Informed consent Treatment ciclosporine , tacrolimus , mycofenolate Treatment anticoagulant Infection Recent start treatment know inhibitor omeprazolemetabolism Moderate severe hepatic impairment ( SGPT and/or AST &gt; 3 time upper limit )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>